Economy
Financial Markets
Commodities
Industries
Energy
Real Estate
Local listed Company
Overseas-listed Company
Foreign Company
Industrial Parks


 
Industrial Parks
 Search News  Or
Acrobiosystems to launch new PD1-PDL1 inhibitor screening assay in China

Jan 13, 2016 (China Knowledge) - Beijing Acrobiosystems Biotechnology Co., Ltd, an international recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy, recently announced that its U.S.-based parent company has launched a PD1-PDL1 inhibitor screening assay kit that will significantly improve efficiency for screening and profiling.

 

Also a specialist in mammalian cell-based recombinant protein production and process development, the biotech firm has its headquarters located in Beijing E-Town.

 

The PD1-PDL1 pathway inhibitor screening kit, the first of its kind in China, works by testing candidate inhibitors' efficiency in blockade of the PD1-PDL1 pathway. The kit is highly sensitive and efficient, and can be repetitively used on a large scale. Removing the need for carrying out parallel comparative experiments as the drug industries used to do, the kit facilitates massive one-time screening. In combination with biotin labelling technology, the kit can help bridge the differences caused by unstable experiment conditions. 

 

This new product is set to hit the market having received rave reviews from several Chinese and foreign drug R&D companies in pre- market tests. Acrobiosystems will launch more immunosuppression pathway assay kits to cater to demand from pharmaceutical companies.

 

Biomedicine, as an emerging industry of strategic significance in China, is one of the ten areas highlighted in a ten-year national plan known as "Made in China 2025" and is also one of the leading industries high on the agenda of Beijing E-Town, a triple-A rated industrial parks in China.

 

In recent years, many high-end biotech firms including Beijing Acrobiosystems have made their headquarters in Beijing E-Town's biomedicine park, allured by its preferential investment policies.

 

In addition, some fortune 500 companies, such as Benz Daimler Chrysler, GE, Bosch, Corning, Danieli, Kimberly-Clark, LG, Cummins, Bayer, ABB, Panasonic, Schneider, SMIC and BOE, have chosen Beijing E-Town as their HQ or R&D base in China.

 

With backing from Beijing Municipal of Science and Technology Commission, Beijing E-Town will attract more investments and expertise in the biomedical industry.







Add this     
Copyright © "2015" www.chinaknowledge.com

Send feedback or comments to: news@chinaknowledge.com

For more news, financial weekly reports, business guides to China, Market Research Reports and other premium information, subscribe to China Knowledge today

To access our page on Bloomberg, type CKFI (GO)

 Our Professional Services

 E-Store

 News Archive
About Us | CSR | Media Center | E-Newsletter | E-Store | Contact Us | Feedback | Sitemap | Privacy Policy | Terms of Use  

           Copyright © 2014 China Knowledge Online. All Rights Reserved